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Autoimmune diseases affect approximately 8% of the
population, 78% of whom are women. The reasons for the
high prevalence in women are unknown, but circumstantial
evidence links autoimmune diseases with preceding infec-
tions. Animal models of autoimmune diseases have shown
that infections can induce autoimmune disease. For exam-
ple, coxsackievirus B3 (CB3) infection of susceptible mice
results in inflammation of the heart (myocarditis) that
resembles myocarditis in humans. The same disease can
be induced by injecting mice with heart proteins mixed with
adjuvant(s), which indicates that an active infection is not
necessary for the development of autoimmune disease.
We have found that CB3 triggers autoimmune disease in
susceptible mice by stimulating elevated levels of proin-
flammatory cytokines from mast cells during the innate
immune response. Sex hormones may further amplify this
hyperimmune response to infection in susceptible persons,
which leads to an increased prevalence of autoimmune dis-
eases in women. 
A
utoimmune diseases are the third most common cate-
gory of disease in the United States after cancer and
heart disease; they affect approximately 5%–8% of the
population or 14–22 million persons (1). Autoimmune dis-
eases can affect virtually every site in the body, including
the endocrine system, connective tissue, gastrointestinal
tract, heart, skin, and kidneys. At least 15 diseases are
known to be the direct result of an autoimmune response,
while circumstantial evidence implicates >80 conditions
with autoimmunity (2). In several instances, such as
rheumatoid arthritis, multiple sclerosis, and myocarditis,
the autoimmune disease can be induced experimentally by
administering self-antigen in the presence of adjuvant (col-
lagen, myelin basic protein, and cardiac myosin, respec-
tively) (3). An important unifying theme in autoimmune
diseases is a high prevalence in women (Figure 1) (4,5).
Conservative estimates indicate that 6.7 million or 78.8%
of the persons with autoimmune diseases are women (4). 
Soon after autoimmune diseases were first recognized
more than a century ago, researchers began to associate
them with viral and bacterial infections. Autoimmune dis-
eases tend to cluster in families and in individuals (a per-
son with one autoimmune disease is more likely to get
another), which indicates that common mechanisms are
involved in disease susceptibility. Studies of the preva-
lence of autoimmune disease in monozygotic twins show
that genetic as well as environmental factors (such as
infection) are necessary for the disease to develop (6).
Genetic factors are important in the development of
autoimmune disease, since such diseases develop in cer-
tain strains of mice (e.g., systemic lupus erythematosus or
lupus in MRL mice) without any apparent infectious envi-
ronmental trigger. However, a body of circumstantial evi-
dence links diabetes, multiple sclerosis, myocarditis, and
many other autoimmune diseases with preceding infec-
tions (Table) (7,8). More often, many different microor-
ganisms have been associated with a single autoimmune
disease, which indicates that more than one infectious
agent can induce the same disease through similar mecha-
nisms (Table) (9). Since infections generally occur well
before the onset of symptoms of autoimmune disease, clin-
ically linking a specific causative agent to a particular
autoimmune disease is difficult (Figure 2). This difficulty
raises the question of whether autoimmune diseases really
can be attributed to infections. 
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Figure 1. Major autoimmune diseases, comparing the incidence of
disease in women (white bar) to the incidence in men (black bar)
by percentage. Modified from (5).Are Autoimmune Diseases 
Caused by Infections?
To address the question of whether autoimmune dis-
eases can be induced by infections, first autoimmunity
needs to be defined. Autoimmune disease occurs when a
response against a self-antigen(s) involving T cells, B
cells, or autoantibodies induces injury systemically or
against a particular organ. Understanding of autoimmune
diseases is hindered by the fact that some level of autoim-
munity, in the form of naturally occurring autoantibodies
and self-reactive T and B cells, is present in all normal per-
sons (6). Thus, on a proportional basis, developing autoim-
mune disease is the relatively uncommon consequence of
a common autoimmune response. Although an autoim-
mune response occurs in most persons, clinically relevant
autoimmune disease develops only in susceptible persons
(Figure 2).
Given those circumstances, how can infections induce
autoimmune disease? A mechanism often called on to
explain the association of infection with autoimmune dis-
ease is “molecular mimicry,” that is, antigens (or more
properly epitopes) of the microorganism closely resemble
self-antigens. The induction of an immune response to the
microbial antigen thus results in cross-reaction with self-
antigens and induction of autoimmunity (10). Although
epitope-specific cross-reactivity between microbes and
self-tissues has been shown in some animal models
(11,12), molecular mimicry has not been clearly demon-
strated to occur in human diseases (13). Another possibili-
ty is that microorganisms expose self-antigens to the
immune system by directly damaging tissues during an
active infection. This mechanism has been referred to as
the “bystander effect” (14,15). However, whether
pathogens mimic self-antigens, release sequestered self-
antigens, or both, is difficult to determine. 
In addition to antigen-specific mechanisms, nonspecif-
ic mechanisms could also lead to autoimmunity after infec-
tion (9,16). Activation of the innate immune system is
essential for a protective adaptive immune response to
develop; and vaccines that lack intrinsic activation of
innate immunity (e.g., subunit vaccines) require microbial
adjuvants to be immunogenic (17). Historically, adjuvants
are considered to stimulate immune responses nonspecifi-
cally. Arenewed understanding of the critical role of innate
immunity in influencing the development of an adaptive
immune response has led researchers to a better under-
standing of “the adjuvant effect” (16). Although innate
immune cells do not respond to specific antigenic epitopes
on pathogens, they do produce restricted responses to par-
ticular classes of pathogens through pattern-recognition
receptors (PRR), such as Toll-like receptors (TLR) (18).
Interaction of the microorganism component of adjuvants
with PRR on innate immune cells results in activation of
antigen-presenting cells and upregulation of molecules
essential for antigen presentation, such as major histocom-
patibility complex (MHC) class II and B7–1/2, as well as
production of proinflammatory cytokines. This activation
of PRR by the microbial components of adjuvants stimu-
lates the immune response in a manner similar to
pathogens such as bacteria or viruses (16,18). The
pathogen-specific innate immune response is not the same
as the nonspecific activation that occurs after mechanical
tissue damage, such as during surgery. During mechanical
injury, self-antigens and cytokines are released without
consistently stimulating pathogen-specific responses.
Autoimmune disease rarely develops and usually resolves
spontaneously, as seen in postcommissurotomy syndrome
(or postcardiotomy syndrome). Adjuvants (usually bacter-
ial, e.g., Mycobacterium in complete Freund’s adjuvant)
activate the innate immune response in the same pathogen-
specific manner when administered with self-antigen; this
process results in organ-specific autoimmune disease in
animal models (9,16). Adjuvant alone (without self-
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Figure 2. Infections occur before the onset of symptoms of autoim-
mune disease, making links to specific causative agents difficult.
When a person is first infected (day 0), usually no symptoms are
apparent. Signs and symptoms of autoimmune disease are clear-
ly present and easily confirmed by physicians during the chronic
stage of autoimmunity. However, the infection has been cleared by
this time, making it difficult to establish that an infection caused the
autoimmune disease. Modified from (16).antigen) does not usually result in autoimmune disease,
and microorganisms likely provide not only the adjuvant
effect to stimulate the immune response but also the dam-
age necessary to make self-antigens available to the
immune system, resulting in autoimmune disease. 
To determine whether infection can lead to autoimmune
disease, direct evidence (e.g., the ability to transfer autoim-
mune disease), indirect evidence (e.g., the ability to repro-
duce autoimmune disease in animal models), and circum-
stantial evidence (e.g., the association of autoantibodies
with disease in appropriate clinical settings) should be con-
sidered (3,6). The best evidence so far that infections can
induce autoimmune diseases comes from animal models.
In most animal models of autoimmunity, including
myocarditis, disease has been transferred to naïve animals
with autoimmune cells (splenocytes or T cells), autoanti-
bodies (7), or both, which provides compelling evidence
that infections induce autoimmune diseases by immune-
mediated mechanisms. 
Lessons from Coxsackievirus B3 
(CB3) Myocarditis 
Genetics of Susceptibility to Myocarditis 
Genetic background accounts for only about one third
(30%–35%) of the risk of autoimmune disease (6,19). This
estimate is based on studies that compared genetically
identical, monozygotic twins to nonidentical, dizygotic
pairs, for which the concurrence rate can be as low as 2%
to 7% (19). Therefore, noninherited factors account for the
remaining (approximately 70%) risk of developing an
autoimmune disorder. Yet, even identical twins do not have
identical immune systems. Genes outside of the MHC con-
tribute to the risk for autoimmune disease. However, little
information is available about the function of these non-
MHC genes. Recent studies have focused on regulatory
signals, and considerable evidence exists that cytotoxic
lymphocyte antigen–4 (CTLA-4), which provides a down-
regulatory signal, influences susceptibility to autoimmuni-
ty (20). Genes that involve apoptosis, a common pathway
by which immune responses generally are terminated, may
also predispose persons to autoimmune disease (6). 
To better understand the relationship between infection
and autoimmune disease, we established a mouse model
of myocarditis, or inflammation of the heart, induced by
CB3 infection (9). CB3 is believed to account for most
cases of myocarditis in North America and Europe;
myocarditis also leads to dilated cardiomyopathy, which
can result in heart failure and the need for a heart trans-
plant (21). The same strain of CB3 that induces myocardi-
tis in humans also induces disease in mice, which makes
it an ideal pathogen to study. We found that susceptibility
to myocarditis is due primarily to genes that are not part
of the MHC (22). Our initial investigations into the genet-
ic predisposition of autoimmune myocarditis involved
infecting many inbred mouse strains with CB3 (22).
Genetic analysis comparing susceptibility loci between
susceptible and resistant strains of mice found that sus-
ceptibility to myocarditis is associated with genes on
mouse chromosomes 1 and 6 that have been previously
associated with other autoimmune diseases in mice and
humans (M. Guler and N.R. Rose, unpub. data). In sus-
ceptible strains of mice ( e.g., BALB/c, A/J), acute heart
inflammation develops approximately 7–12 days after
infection; the inflammation resolves by day 21, and then a
chronic phase of inflammation and dilated cardiomyopa-
thy develops from day 35 (9). In contrast, only the acute
phase of the disease develops in resistant strains like
C57BL/6. After mice are infected with CB3, autoantibod-
ies are produced against cardiac myosin, the major com-
ponent of heart muscle. We found that susceptible strains
of mice produce higher titers of immunoglobulin (Ig) G
autoantibodies that are specific for cardiac, but not skele-
tal, myosin, with an IgG1 response (T-helper 2
[Th2])–type) being prominent (9). The predominant cellu-
lar infiltrate during the acute phase of CB3-induced
myocarditis includes macrophages, neutrophils, CD4+ T
cells, and CD8+ T cells (S. Frisancho-Kiss, et al., unpub.
data). Smaller numbers of natural killer cells, B cells, and
eosinophils are also present. Both T-cell–mediated and
autoantibody-mediated mechanisms have been shown to
be important in the development of CB3-induced heart
disease in BALB/c mice (9). 
Knowing that cardiac myosin/adjuvant immunization
induces myocarditis similar to CB3 infection, we exam-
ined the myosin sequences responsible for disease induc-
tion. We found that none of the cardiac myosin sequences
were cross-reactive with viral sequences (23).
Furthermore, cross-reactivity between antibodies induced
by myosin immunization or CB3 infection was not
observed, which suggests that molecular mimicry is not a
predominant mechanism in the development of CB3-
induced myocarditis (13,15,23). Viral infections can
induce damage to host tissues by direct (e.g., viral replica-
tion) or indirect (e.g., nitric oxide) mechanisms. In our
model of CB3 myocarditis, however, we did not observe
damage to the heart cells during the acute phase of disease
(9,24). We found that CB3 replicates at a relatively low
level in the heart and that necrosis and fibrosis did not
appear until the chronic phase of disease, after virus had
been cleared from the heart (25). Thus, a low level of viral
replication is sufficient to provide cardiac myosin to the
immune system. Overall, our studies of CB3-induced
myocarditis favor the hypothesis that autoimmune disease
is induced after viral infection of susceptible mice because
the pathogen facilitates the release of cardiac myosin and
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manner similar to the effect of adjuvants (16). 
Is Virus Associated with Myocarditis?
Many different microorganisms (e.g., streptococci,
Trypanosoma, cytomegalovirus [CMV], and CB3) have
been associated with the same autoimmune disease (e.g.,
myocarditis) (Table). We have shown that two completely
different viruses (CB3, a small nonenveloped RNA virus,
and murine CMV, a large enveloped DNA virus) induce a
similar biphasic myocarditis in susceptible BALB/c mice
(9). Although infectious CB3 or murine CMV (MCMV)
can be detected during the acute phase of myocarditis,
viral levels do not correlate with the severity of inflamma-
tion (9,26,27). Because viral genome can be detected after
infectious virus has been cleared from the heart, latent
virus may attract inflammation during the chronic stage of
disease. However, when we examined the heart for the
presence of latent MCMV, we found that viral genome and
transcript were present in mice both susceptible to and
resistant to the development of chronic disease (27). These
results indicate that persistence of virus alone is not the
determining factor in the development of chronic
myocarditis. Yet the best evidence that active viral infec-
tion is not required for myocarditis to develop comes from
the demonstration that injecting susceptible mice with car-
diac myosin emulsified in adjuvant induces experimental
autoimmune myocarditis (24). In fact, the pathogenesis of
experimental autoimmune myocarditis closely resembles
the biphasic myocarditis associated with CB3 or MCMV
infection. This finding indicates that the adjuvant effect
produced by infections or adjuvants during the innate
immune response can lead to the development of autoim-
mune disease when self-antigen is present. We have found
in preliminary studies that the same pattern of TLR expres-
sion is induced by CB3 and the Mycobacterium in com-
plete Freund’s adjuvant, which suggests a common mech-
anism of activation (16).
Proinflammatory Cytokines Determine 
the Development of Myocarditis
Key to understanding the control of susceptibility to
autoimmune myocarditis was the finding that adding bac-
terial lipopolysaccharide (LPS), interleukin (IL)-1β, or
tumor necrosis factor (TNF)-α during the innate response
to CB3 infection results in the development of the chronic
phase of disease in resistant strains of mice (28,29). Thus,
by increasing proinflammatory cytokine production during
the innate immune response to infection, genetic resistance
to the development of autoimmune disease can be altered.
We have found that susceptible BALB/c mice have signif-
icantly increased levels of the proinflammatory cytokines
TNF-α (Figure 3A) and IL-1β (Figure 3B) in the heart dur-
ing acute CB3 myocarditis. In fact, many autoimmune dis-
eases, such as rheumatoid arthritis, are associated with
increases in TNF-α and IL-1β levels, and treatments that
block these cytokines have proven beneficial in animal
models and clinical settings (30). We have a long-standing
interest in the adjuvant effect of lipopolysaccharide (LPS)
on the development of autoimmune disease (28,29,31), but
only recently has LPS been shown to mediate its effects in
part by increasing TNF-α, IL-1β, and IL-18 levels through
TLR4 signaling (18). Recently, we demonstrated that CB3
infection increases IL-1β and IL-18 levels in the heart dur-
ing acute myocarditis through IL-12Rβ1 and TLR4 signal-
ing (26). Furthermore, the severity of acute myocarditis
directly correlates with increased levels of IL-1β and IL-18
in the heart (26). Similarly, in the experimental autoim-
mune myocarditis model, IL-12Rβ1 signaling and
increased IL-1β levels are associated with the development
of myocarditis (24). This effect of LPS or TNF-α on the
development of myocarditis is not limited to CB3 infec-
tion, but is also observed following MCMV infection (32).
Thus, proinflammatory cytokine production is key in
determining whether susceptible strains of mice develop
autoimmune disease after infection. 
Innate Immune Response Initiates Myocarditis 
Since the innate immune response is critical in deter-
mining the development of adaptive immunity (18) and
proinflammatory cytokines administered during the innate
response determine whether chronic myocarditis develops,
we were interested in studying early differences in the
cytokine response to CB3 infection in susceptible
(BALB/c) or resistant (C57BL/6) mice to see if they could
provide clues to the progression to autoimmunity. We
found that susceptible and resistant mice produce the same
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Figure 3. Proinflammatory cytokines are increased in the hearts of
susceptible mice during acute myocarditis. Susceptible BALB/c
mice were compared to resistant C57BL/6 mice for the level of
cytokines tumor necrosis factor (TNF)-α (A) and interleukin (IL)-1β
(B) in heart homogenates 12 days after CB3 infection. Data are
represented as the mean ± standard error of the mean. *p < 0.05.cytokine profile during the innate immune response to
CB3 infection but that susceptible mice have significantly
higher levels of cytokines in the heart (Figure 4) and
spleen (33). The proinflammatory cytokines TNF-α
(Figure 4A) and IL-1β (Figure 4B) are significantly
increased in susceptible BALB/c mice at 6 and 12 hours
after CB3 infection, during the innate immune response.
Surprisingly, IL-4 (the prototypic Th2 type cytokine) is
also significantly increased 6 hours after CB3 infection
(Figure 4C). According to the current dogma, inflammato-
ry autoimmune diseases such as myocarditis are primarily
attributable to Th1 responses, with interferon (IFN)-γ as
the prototypic cytokine; Th2 responses where IL-4 domi-
nates are believed to reduce autoimmunity. Although pro-
tection against viral infections is usually associated with
Th1 responses attributable to the protective effect of IFN-
γ, in fact, a number of viral infections produce a mixed
Th1/Th2 profile, including CB3 (24, 25,33). We also
observe a mixed Th1/Th2 cytokine profile in the experi-
mental autoimmune myocarditis model (24,34).
An elevated IL-4, TNF-α, and IL-1β response is remi-
niscent of the hypersensitivity reaction of mast cells during
allergic responses (35). Mast cells are known to produce a
rapid burst of cytokines (e.g., TNF-α, IL-1β, and IL-4)
when stimulated through TLRs such as TLR2 and TLR4
(36). When we looked for mast cells in the spleen 6 hours
after CB3 infection, we found that susceptible BALB/c
mice had significantly more mast cells than resistant
C57BL/6 mice (Figure 5) (33). We also found that TLR4 is
increased on mast cells of susceptible mice immediately
after infection (16). Thus, the increased innate cytokine
response to CB3 in susceptible mice may be due to a mast
cell–mediated response to pattern recognition sequences
on CB3 (16,18,33), similar to an allergic reaction. Since
the innate immune response determines whether the chron-
ic phase of myocarditis and dilated cardiomyopathy devel-
op in mice (29,32), early activation of mast cells may
result in a delayed-type hypersensitivity reaction later, dur-
ing the chronic phase of the disease (25). Mast cells are
found in the human heart in increased numbers during car-
diovascular disease and congestive heart failure (37). We
have also observed increased numbers of degranulating
mast cells during chronic CB3 myocarditis in susceptible
mice with severe disease (25). So the evidence presented
by the CB3-induced model of myocarditis demonstrates
that virus can trigger autoimmune disease in susceptible
mice by immune-mediated mechanisms. But the question
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Figure 4. Proinflammatory cytokines are increased in the hearts of
susceptible mice during the innate immune response. Susceptible
BALB/c mice were compared to resistant C57BL/6 mice for the
level tumor necrosis factor (TNF)- α (A), interleukin (IL)-1β (B),
and IL-4 (C) cytokines in heart homogenates 6 and 12 hours after
CB3 infection. Data are represented as the mean ± standard error
of the mean. *p < 0.05; ***p < 0.001. Modified from (33).
Figure 5. Mast cells are increased in the spleens of susceptible
BALB/c mice 6 hours after CB3 infection. Data are represented as
the mean ± standard error of the mean. ***p < 0.001. Modified from
(33). still remains: Why are autoimmune diseases so prevalent
in women? 
Why Are Autoimmune Diseases 
So Prevalent in Women?
Even though women’s greater susceptibility to autoim-
mune diseases has been recognized for more than 100
years, only recently has attention focused on this topic (5).
For some time, the basic immune response between men
and women has been known to differ, with women produc-
ing a more vigorous immune response and increased anti-
body production (5,38). However, autoimmune diseases
that develop in men often are more severe (39). Most of
our understanding of sex differences in the immune
response comes from work done in animal models. Many
animal models of autoimmune disease have shown a simi-
lar sex bias, with a higher incidence of disease in women.
Sex hormones, such as estrogen, testosterone, and proges-
terone, may mediate most of the sex-biased differences in
the immune response (39). Recently, estrogens and andro-
gens have been found to directly influence whether a Th1-
or Th2-type immune response develops by interacting with
hormone receptors on immune cells (38). Not only are a
variety of sex hormone receptors found on immune cells,
but cytokine receptors (e.g., IL-1R, IL-18R) have likewise
been discovered on hormone-producing tissues, which
suggests bidirectional regulation of the immune response.
Furthermore, proinflammatory cytokines such as TNF-α
and IL-1β stimulate the release of glucocorticoids from the
hypothalamus-pituitary-adrenal axis, which regulates the
inflammatory process, along with androgens and estrogens
(40). 
The precise interaction between hormones and the innate
immune response after infection is poorly understood.
However, in vitro studies of immune cells cultured in the
presence of hormones have shown that estrogen significant-
ly increases proinflammatory cytokine production (e.g.,
TNF-α, IL-1β) (5). In preliminary experiments studying the
role of sex hormones on the development of CB3-induced
myocarditis in mice, we have found that sex hormones
increase inflammation and proinflammatory cytokines in
the hearts of male and female mice after infection.
Gonadectomy before CB3 infection reduces myocarditis in
female (Figure 6A) and male mice (Figure 6B). Reduced
inflammation is associated with reduced TNF-α in the
female heart (Figure 6C) and reduced IL-1β in the male
heart (Figure 6D). Thus, the elevated immune response in
women may even further amplify the adjuvant effect of
infection, thereby increasing the possibility that chronic,
autoimmune disease will subsequently develop in women.
With the increase in the number of autoimmune cases in
recent years, the possible role of infections in exacerbating
disease, particularly in women, is of rising concern.
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